Search for Clinical Trial Results

Sponsored By

Pancreatic Neuroendocrine Tumor - 25 Studies Found

Status Study
Active, not recruiting Study Name: Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Date: 2014-09-02
Interventions:
  • Drug: Lanreotide Autogel 120 mg

Completed Study Name: 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Date: 2014-06-03
Interventions: Drug: 68Ga-OPS202
Completed Study Name: 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Date: 2013-04-25
Interventions: Drug: Intravenous injection of 177Lu-octreotate Treatment will consist of 177Lu-octreotate injections in
Completed Study Name: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Date: 2010-12-16
Interventions:
  • Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus
Not yet recruiting Study Name: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Condition:
  • Neuroendocrine Tumors
  • Neuroendocrine Carcinoma
  • Temozolomid
    Date: 2017-03-09
    Interventions: Drug: TEMCAP Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a
Completed Study Name: Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Condition:
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine
    Date: 2016-10-27
    Interventions: Procedure: NETest 5 mL of blood will be drawn from participants for testing.
Active, not recruiting Study Name: The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Condition:
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Secondary Malignan
    Date: 2011-08-24
    Interventions: Other: magnetic resonance imaging (MRI) Each patient will
Active, not recruiting Study Name: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumor
Date: 2007-12-17
Interventions:
  • Drug: RAD001 Given orally once
Completed Study Name: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Date: 2010-05-10
Interventions: Drug: Sunitinib Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg
Active, not recruiting Study Name: A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Date: 2012-01-13
Interventions: Drug: sunitinib Sunitinib capsules will be given orally at continuous daily dosing with a starting dose
<<< Previous | Next >>>